Abstract

Provided are pharmaceutical compositions for treating cancer patients. The pharmaceutical compositions include a combination of compounds inhibiting PTP1 b activity and chemotherapeutic agents. The PTP 1 b inhibitors in such pharmaceutical compositions can include a small molecule such as an anti-sense inhibitor, an allosteric/reversible inhibitor, and/or a permanent/chemical modification inhibitor. Methods of treating subjects are also provided. Such treatment methods include administering to a subject in need of treatment a pharmaceutical composition including one or more compounds inhibiting PTP1b activity and one or more chemotherapeutic agents. Also provided herein are methods of restoring an anti-tumor immune response in a subject receiving chemotherapy, including administering to the subject a PTP 1 b inhibitor prior to, during and/or after receiving a chemotherapeutic agent, whereby an anti-tumor immune response in the subject is restored and/or enhanced.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 33/243 - PlatinumCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present inventive concept provides methods and tools for determining opioid responsiveness and overcoming opioid desensitization in pain including, but not limited to, acute pain, chronic pain, opioid resistant neuropathic pain, and spinal cord injury pain, by identifying the metabolomic profile of the dopaminergic system in opioid responsive and opioid non-responsive subjects.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

Provided herein according to some embodiments are modified dengue virus E proteins, compositions comprising the modified dengue virus E proteins, and methods of use. The modified dengue virus E protein comprise three or more amino acid substitutions that enable a tetravalent mixture of DENV1, DENV2, DENV3, and DENV4 serotypes without formation of E protein heterodimers that lower immunogenic efficacy of the E proteins.

IPC Classes  ?

• C07K 14/01 - DNA viruses
• A61K 39/12 - Viral antigens

Abstract

The present invention relates to ligands for M-phase phosphoprotein (MPP8) and pharmaceutical compositions thereof and their utility as anti-cancer agents.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents

Abstract

Described is small molecule N-(l-isopropylpiperidin-4-yl)-6-methoxy-2-morpholino-7- (3-(pyrrolidin-l-yl)propoxy)quinolin-4-amine)) (MS 1262) that inhibits methyltransferases G9a/GLP. This inhibitor can be used for the treatment of patients with G9a/GLP related diseases such as Alzheimer's Disease and Prader-Willi Syndrome.

IPC Classes  ?

• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

A system for determining a physical characteristic or measuring a physical activity of a subject using back-illumination of an eye of a subject includes at least one light source configured for illuminating an eye of a subject using light from within the head of the subject. The system further includes at least one light sensor positionable outside of the head of the subject for sensing light from the at least one light source exiting the subject through the eye of the subject. The system further includes a controller coupled to the at least one light source and to the at least one light sensor for recording an indication of the light while controlling the illuminating.

IPC Classes  ?

• A61B 3/00 - Apparatus for testing the eyesInstruments for examining the eyes
• A61B 3/13 - Ophthalmic microscopes
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/0205 - Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnicsTesting reaction times

Abstract

A microfluidic device includes a plurality of reaction wells; and a plurality of solid supports, and each of the solid supports has a reagent attached thereto. The reagent is attached to the solid support via a labile reagent/support bond such that the reagent is configured to be cleaved from the support via a cleaving operation.

IPC Classes  ?

• C12Q 1/6823 - Release of bound markers
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• B01L 7/00 - Heating or cooling apparatusHeat insulating devices
• C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
• C12Q 1/686 - Polymerase chain reaction [PCR]
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor

Abstract

Disclosed herein are devices, apparatuses and methods for generating self-sustaining gaseous and non-gaseous gradients across a cell support structure and for culturing one or more cells or tissues under hypoxic conditions. Methods of generating one or more gas gradients across a cell support structure include providing a luminal container having a bottom wall that is a gas permeable membrane, positioning a cell support structure above the bottom wall, positioning one or more cells or tissues on the cell support structure, and generating one or more gas gradients between the bottom wall, across the cell support structure and into a luminal reservoir. An apparatus to produce hypoxic conditions for cell cultures includes a luminal container having a bottom wall, a cell support structure on the bottom wall, and a cover that sealably closes the open top, such that a hypoxic condition can be generated in the luminal reservoir.

IPC Classes  ?

• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Decoding methods are provided for identifying populations in assays, particularly multiplexing assays and those associated with fluidic devices.

IPC Classes  ?

• G01N 33/542 - ImmunoassayBiospecific binding assayMaterials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

The present invention provides compositions and formulations comprising glutathione with or without thiocyanate and methods of use thereof to treat diseases and disorders in mucosal/epithelial tissue.

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A01N 1/02 - Preservation of living parts
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
• A61K 31/375 - Ascorbic acid, i.e. vitamin CSalts thereof
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 33/04 - Sulfur, selenium or telluriumCompounds thereof
• A61K 33/10 - CarbonatesBicarbonates
• A61K 38/40 - Transferrins, e.g. lactoferrins, ovotransferrins
• A61K 38/44 - Oxidoreductases (1)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for disrupting a blood clot with ultrasound and at least one cavitation enhancing agent includes administering at least one cavitation enhancing agent into a blood vessel of a subject. The method further includes monitoring the at least one cavitation enhancing agent to determine when at least a portion of the at least one cavitation enhancing agent has reached a blood clot. The method further includes controlling application of ultrasound energy to the at least one cavitation enhancing agent within the blood vessel of the subject such that, during a first time period, cavitation-enhancing ultrasound energy is not applied to the at least one cavitation enhancing agent within the blood vessel and, during a second time period after the first time period, cavitation enhancing ultrasound energy is applied to the at least one cavitation enhancing agent within the blood vessel.

IPC Classes  ?

• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for

Abstract

Analysis systems with a housing having a chamber sized and configured to receive at least one microfluidic device. The systems also include an optic system coupled to the housing in optical communication with the at least one microfluidic device, a controller coupled to the optic system, a heat source coupled to the optic system and thermally coupled to the at least one microfluidic device held in the housing, and a sub-array selection module in communication with the controller. The sub-array selection module is configured to select a sub-set of sets of microwells of at least one fluid channel of the microfluidic device for imaging by the optic system after a reaction step (e.g., one thermocycle) during an assay.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

e.g.,e.g., spleen) delivery of cargo. Methods of spleen specific delivery of a lipid nanoparticle comprising a cholesterol derivative according to the present invention are also provided.

IPC Classes  ?

• C07J 43/00 - Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta[a]hydrophenanthrene skeleton
• A61K 9/51 - Nanocapsules
• C07J 41/00 - Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring

Abstract

A method for analyzing human leukocyte antigen (HLA) test results to identify clinically relevant changes in test patterns or evaluate HLA testing includes receiving, as input, HLA test results. The method further includes using principal component analysis (PCA) to analyze the HLA test results to detect a clinically relevant change for a subject or evaluate an aspect of HLA testing. The method further includes outputting results of the analysis.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Methods and systems relate to imaging a sample using fluorescence microscopy. An example system includes a light source configured to propagate a light beam, and an illumination system comprising a light guide tip. The light guide tip is positioned over a sample. When the light beam is directed into the light guide tip at a first time instance, a first portion of the light beam is directed towards a first mirror included in the light guide tip, and the first mirror reflects the first portion of the light beam as a first focusing light beam over the sample, causing a fluorescent emission from the sample. The example system further includes an objective lens for receiving the fluorescent emission for imaging the sample.

IPC Classes  ?

• G02B 21/16 - Microscopes adapted for ultraviolet illumination
• G01N 21/64 - FluorescencePhosphorescence
• G02B 21/00 - Microscopes

Abstract

A tool for loosening a clave and a hub that are attached to each other in a seized hub-clave joint and/or for connecting a clave and hub to form a hub-clave joint. The tool has a body and one or more grip areas disposed at different positions along the body. Each grip area includes a grip liner. Some or all of the body is deformable or movable when the clave or the hub is positioned within a corresponding one of the grip areas. The grip liner is used, when the body is deformed, to engage against the clave or the hub inserted within one of the grip areas of the tool, such that a user of the tool can rotate the tool about an axis defined by the corresponding grip area to exert a torque on the clave or the hub engaged by the tool, thereby loosening the seized hub-clave joint.

Abstract

Disclosed herein are mRNA display libraries comprising peptides with non-canonical amino acids and methods of making the mRNA display libraries which may include a plurality of mRNA-linker-macrocyclic peptide molecules comprising AcTyr-[amino acid]m-[PhSec]-[amino acid]n-[Cys]-[linker]-[mRNA]; wherein m and n are each an integer from 0 to 30; and wherein each macrocyclic peptide comprises a thioether linkage and is according to formula I: wherein R comprises [linker]-[mRNA].

Abstract

This disclosure is directed to a method for detecting melanoma in a tissue sample by measuring a level of methylation of one or more regulatory elements differentially methylated in melanoma and benign nevi. The invention provides methods for detecting melanoma, related kits, and methods of screening for compounds to prevent or treat melanoma.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Disclosed are compounds of formulae: Disclosed are compounds of formulae: Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R1, R2, R3, R4, R5, R6, R7, R11, R12, R13, R14, R15, R16, R17, n, and m are defined herein. These compounds are usefμl for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

IPC Classes  ?

• C07C 259/06 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
• A61P 31/04 - Antibacterial agents
• C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
• C07C 259/18 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. N-hydroxyamidines having carbon atoms of hydroxyamidine groups bound to carbon atoms of six-membered aromatic rings
• C07C 311/06 - Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
• C07C 317/18 - SulfonesSulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
• C07C 317/44 - SulfonesSulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• C07D 203/08 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
• C07D 203/18 - Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with acylated ring nitrogen atoms by carboxylic acids, or by sulfur or nitrogen analogues thereof
• C07D 207/327 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 263/16 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
• C07D 277/40 - Unsubstituted amino or imino radicals
• C07D 295/10 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulfur atoms
• C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 309/04 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 309/10 - Oxygen atoms
• C07D 335/02 - Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems

Abstract

Provided herein according to some embodiments are double-stranded RNA molecules comprising a sense strand and an antisense strand with two or more dT overhangs on a 5' end of the antisense strand, and compositions comprising the double-stranded RNAs. Methods of enhancing RNA interference activity at a target are provided, comprising delivering a double-stranded RNA to the target. Methods of treating a disorder or disease are also provided.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose

Abstract

This invention relates to methods and compositions for increasing tear production, increasing tear film stability, increasing the size and/or function of lacrimal glands and meibomian glands, reducing inflammation in the lacrimal gland, treating dry eye, and treating corneal epithelial defects by administering ADM protein or a functional fragment thereof, optionally where the ADM protein or a functional fragment thereof increases the basal tear production, reduces basal tear evaporation, and/or increases basal size and/or basal function of lacrimal glands and meibomian glands.

IPC Classes  ?

• A61K 38/22 - Hormones
• A61P 27/02 - Ophthalmic agents

Abstract

This invention relates to the development of bioorthogonal reactant compounds, e.g., 5-hydroxy strained trans-cyclooctene compounds, and to methods of synthesizing said compounds. Moreover, this invention relates to methods of synthesizing positron emission tomography (PET) imaging probes using the bioorthogonal reactant compounds as described herein, as well as probes produced by the methods. Lastly, this invention relates to methods of detecting a tumor in a subject by administering said bioorthogonal reactant compounds and/or PET probes that are described herein.

IPC Classes  ?

• C07C 235/14 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• A61K 51/04 - Organic compounds

Abstract

This invention relates to the finding that novel splice switching oligonucleotides can correct splicing mutations. Moreover, the invention relates to using the novel splice switching oligonucleotides to correct the c.6547-963G→A mutation in a pre-mRNA produced from the human DNAH11 gene and methods of using the same for treatment of primary ciliary dyskinesia (PCD) in a subject.

Abstract

The present document provides methods for post-polymerization modification of polymer backbones. In particular, the methods described in this document relate to transformation of polyesters and polyurethanes via [3,3]-sigmatropic rearrangement. Polymer compounds containing backbones modified post-polymerization are also provided, along with various methods of using these polymers in a variety of segments of the economy.

IPC Classes  ?

• C08G 63/88 - Post-polymerisation treatment
• C08G 18/82 - Post-polymerisation treatment

Abstract

This invention relates to the finding that novel splice switching oligonucleotides can correct splicing mutations. Moreover, the invention relates to using the novel splice switching oligonucleotides to correct the c.1167+1262A→G mutation in a pre-mRNA produced from the human CCDC39 gene and methods of using the same for treatment of primary ciliary dyskinesia (PCD) in a subject.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The presently-disclosed subject matter relates to crosslinkers, compositions, and methods for trapping a target of interest on a substrate of interest. The methods may be used to inhibit and treat pathogen infection and provide contraception. The methods may be used to trap or separate particles and other substances. The subject matter further relates to methods of identifying and preparing optimal crosslinkers and methods for manipulating targets of interest.

IPC Classes  ?

• C07K 16/12 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from bacteria
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07K 16/08 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C07K 16/44 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Compositions and methods of making engineered antibody fusion proteins with redox-sensitive domains with modulable binding affinity and devices for the continuous in vivo detection of target molecules are described.

IPC Classes  ?

• C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
• C07K 14/415 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from plants

Abstract

Described are enzyme fuel cells and batteries comprising an anode with a multicopper oxidase enzyme immobilized with a phenolic substrate.

IPC Classes  ?

• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts
• H01M 4/90 - Selection of catalytic material
• C12N 11/14 - Enzymes or microbial cells immobilised on or in an inorganic carrier
• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase

Abstract

Sensors, kits, and methods are disclosed for assaying L-DOPA with an engineered multicopper oxidase. The engineered multicopper oxidase has improved catalytic activity at room temperature and can selectivity dehydrogenate L-DOPA as a substrate when immobilized on an electrode for electrochemical detection.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• G01N 27/327 - Biochemical electrodes
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals
• C12Q 1/26 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase

Abstract

Described are copper dehydrogenase enzymes that are engineered from multicopper oxidases to have reduced oxidase activity. The oxygen-insensitive copper dehydrogenases catalyze the dehydrogenation of a phenolic substrate on an electrode to generate electrical current. Compositions, devices, kits, and methods are disclosed for assaying L-DOPA with a copper dehydrogenase. Anodes, enzyme fuel cells and batteries are disclosed with the copper dehydrogenase immobilized with a substrate.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• G01N 27/327 - Biochemical electrodes
• C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase
• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• H01M 8/16 - Biochemical fuel cells, i.e. cells in which microorganisms function as catalysts
• H01M 4/90 - Selection of catalytic material

Abstract

Compositions, devices, kits, and methods are disclosed for assaying R-3-hydroxybutyrate (BHB) with R-3-hydroxybutyrate binding protein (BHBBP). BHBBPs are derived from several microorganisms to bind BHB specifically, and methods to prepare BHBBPs are disclosed. Methods of determining the concentration BHB in a sample based on fluorometry and electrochemically are also disclosed. Methods and devices to monitor BHB using BHBBP modified electrodes are also disclosed.

IPC Classes  ?

• C07K 14/195 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria
• G01N 21/62 - Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
• G01N 27/30 - Electrodes, e.g. test electrodesHalf-cells

Abstract

The present disclosure relates to a modified glucose dehydrogenase according to one embodiment of the invention comprises a catalytic subunit, an electron transfer subunit, and a hitchhiker subunit, wherein a carbon nanotube binding peptide (CNTBP) is fused to at least one of the catalytic subunit, the electron transfer subunit, and the hitchhiker subunit; an enzyme electrode comprising a carbon nanotube and the modified glucose dehydrogenase; and a biosensor comprising the enzyme electrode.

IPC Classes  ?

• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• C12N 9/00 - Enzymes, e.g. ligases (6.)ProenzymesCompositions thereofProcesses for preparing, activating, inhibiting, separating, or purifying enzymes

Abstract

The present disclosure relates to a biosensor comprising an enzyme electrode comprising a direct electron transfer type oxidoreductase wherein said enzyme electrode is electrically connected to a gate electrode of a field effect transistor (FET), and a method of measuring a substance using the biosensor.

IPC Classes  ?

• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]

Abstract

The present disclosure relates to a biosensor comprising: a first coil which is electrically connected to an enzyme electrode and a reference electrode and transmits a signal generated via an enzyme reaction on the enzyme electrode; and a second coil which is placed proximate to the first coil and is connected to a detection device which receives the signal from the first coil, wherein said enzyme electrode comprises a direct electron transfer type oxidoreductase.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
• G01N 27/327 - Biochemical electrodes

Abstract

The subject matter described herein relates to hole transport layers that contain one or more lead chelating molecules, multilayer perovskite composites comprising the hole transport layers, methods for preparing the multilayer perovskite composites, and use of the multilayer perovskite composites in photovoltaic (PV) devices, such as perovskite solar cells.

IPC Classes  ?

• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
• H01L 31/075 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PIN type, e.g. amorphous silicon PIN solar cells
• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
• H10K 30/81 - Electrodes

Abstract

Disclosed herein are modified protein disulfide isomerases (PDIs) or functional fragments thereof wherein the modified PDI or functional fragment thereof comprises a deletion of an endoplasmic reticulum (ER) signal sequence from a wild-type PDI or functional fragments thereof, and methods of making and using the same. The modified PDI or functional fragment thereof may be used to treat diseases associated with protein aggregates, including neurodegenerative diseases, muscular diseases, injuries, and aging-related conditions.

IPC Classes  ?

• C12N 9/90 - Isomerases (5.)
• A61P 3/00 - Drugs for disorders of the metabolism

Abstract

The present disclosure relates to the general synthesis of amides, amines, esters, ethers, carboxylic acids, aldehydes and alcohols from alkene feedstock under mild conditions using a cobalt catalyst in a carbon monoxide atmosphere and light.

IPC Classes  ?

• C07B 43/06 - Formation or introduction of functional groups containing nitrogen of amide groups
• C07D 295/185 - Radicals derived from carboxylic acids from aliphatic carboxylic acids
• C07C 231/14 - Preparation of carboxylic acid amides by formation of carboxamide groups together with reactions not involving the carboxamide groups
• C07B 41/12 - Formation or introduction of functional groups containing oxygen of carboxylic acid ester groups
• C07B 41/06 - Formation or introduction of functional groups containing oxygen of carbonyl groups
• C07C 235/06 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 233/58 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
• C07C 233/05 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07D 471/08 - Bridged systems
• C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings

Abstract

The present disclosure provides methods, compositions, systems, or kits for treating or delaying the progression of cancer. Particularly, the disclosure relates to therapeutic bispecific binding molecules (e.g., bispecific antibodies) that target cancer cell membrane components and anti-inflammatory or tumorigenic cytokines or chemokines or T cell activators.

Abstract

Aspects of the present disclosure include polymeric structures (e.g., microneedles) having a lattice microstructure composed of one or more lattice cell units. Polymeric structures according to certain embodiments have repeating lattice cell units that are formed by high resolution continuous liquid interface production. Aspects also include systems for making polymeric structures having a lattice microstructure. Systems according to certain embodiments include a micro-digital light projection system having a light beam generator component and a light projection monitoring component and a liquid interface polymerization module having a build elevator and a build surface configured for generating the polymeric lattice microstructure from a polymerizable composition positioned therebetween. Methods for making polymeric structures having a lattice microstructure with the subject systems are also provided. Patches having an array of polymeric microneedles for applying to a skin surface of a subject are also described. In some embodiments, patches include microneedles that contain an active agent compound (e.g., an immunogenic active agent). Methods for applying the patches to the skin surface of a subject are also described.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• B29C 64/135 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified characterised by the energy source therefor, e.g. by global irradiation combined with a mask the energy source being concentrated, e.g. scanning lasers or focused light sources
• B29C 64/232 - Driving means for motion along the axis orthogonal to the plane of a layer
• B29C 64/255 - Enclosures for the building material, e.g. powder containers
• B29C 64/268 - Arrangements for irradiation using laser beamsArrangements for irradiation using electron beams [EB]
• B29K 23/00 - Use of polyalkenes as moulding material
• B29L 31/00 - Other particular articles
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - Apparatus for additive manufacturingDetails thereof or accessories therefor
• B33Y 70/00 - Materials specially adapted for additive manufacturing
• B33Y 80/00 - Products made by additive manufacturing
• C08F 122/10 - Esters

Abstract

in vivoin vivo are also provided. Methods of identifying a compound to treat and/or prevent Type-1 diabetes (T1D) or related condition in a subject, including identifying a compound that blocks G9a translational regulation of β cell autoimmunity, are also provided.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

The invention relates to monoclonal antibodies or an antigen binding fragment thereof targeting acetylation sites within the human Tau protein. K280 and K311, which can be indicative of a disease state and, as such, represent diagnostic and/or therapeutic targets. Accordingly, one aspect of the invention relates to a monoclonal antibody or an antigen binding fragment thereof that specifically binds acetylated lysine 280 or acetylated lysine 311 in human tau protein. The monoclonal antibody or an antigen binding fragment thereof can be part of a pharmaceutical composition and provided to a subject to diagnose and/or treat a tauopathy.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The invention relates to chimeric AAV capsids targeted to oligodendrocytes, virus vectors comprising the same, and methods of using the vectors to target oligodendrocytes.

IPC Classes  ?

• A61K 35/76 - VirusesSubviral particlesBacteriophages
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors
• C12N 15/864 - Parvoviral vectors

Abstract

This invention relates to methods and compositions for gene therapy. In particular, the invention relates to compositions for enhancing delivery of therapeutic products to bystander cells that have not received the expression vector encoding the therapeutic product. The invention further relates to methods of treating disorders using the compositions of the invention.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/10 - Transferases (2.)

Abstract

This invention relates to viral vectors for delivery of iduronate-2-sulfatase (IDS) to a subject. In some aspects the IDS sequence is optimized for expression in human cells. The invention further relates to methods of using the vector to increase secretion of IDS from a cell and for treatment and prevention of mucopolysaccharidosis II.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 3/00 - Drugs for disorders of the metabolism
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/86 - Viral vectors

Abstract

Disclosed herein are compositions, devices, systems, and methods for detection of a target virus via Surface Enhanced Raman Spectroscopy (SERS) using a peptide-modified nanostructured metal.

IPC Classes  ?

• G01N 21/65 - Raman scattering

Abstract

Described herein, inter alia, are MRGPRX2 antagonists and uses thereof.

IPC Classes  ?

• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

Abstract

Provided are multifunctional compound cores that can be functionalized with specific R groups to act as theranostic agents, i.e., for the imaging and/or treating of a cancer in a subject. Methods of synthesizing said compounds and methods of treating a subject by administering a compound that is described herein are also provided.

IPC Classes  ?

• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 51/08 - Peptides, e.g. proteins
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein according to some embodiments a hybrid antibiotic molecule that may be resistant to multi-drug resistance. Dry powder and hydrogel formulations of the hybrid antibiotic molecules are disclosed. Also provided herein is a method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the hybrid antibiotic molecule or a pharmaceutical composition comprising the hybrid antibiotic molecule, thereby treating the bacterial infection in the subject.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/33 - Heterocyclic compounds

Abstract

Aspects of the present disclosure include polymeric structures having one or more polymeric microneedles. Polymeric structures according to certain embodiments include a microstructural component configured to facilitate one or more of insertion of the polymeric microneedle into a skin surface of a subject; retention of the polymeric microneedle in the skin of the subject; creating a seal when the polymeric microneedle is inserted into the skin of the subject; and delivery of an active agent to a subject through the polymeric microneedle. Methods for applying a polymeric structure having polymeric microneedles to a skin surface of a subject is also described. Methods for making the polymeric structures, such as by high resolution continuous liquid interface production are also provided. Kits having one or more of the subject polymeric structures are also described.

IPC Classes  ?

• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

This invention relates to modified adenovirus-associated virus (AAV) capsid proteins with enhanced transduction efficiency and enhanced ability to evade neutralizing antibodies, AAV vectors comprising the same, and methods of using the same for delivery of nucleic acids to a cell of a joint or a joint of a subject.

Abstract

e.g.in vitro,in vivo ex-vivoe.g.e.g., adenosine triphosphate), or derivative, metabolite, analog, or precursor thereof, with a nucleic acid are provided. Methods of using the compositions to increase efficacy of the delivered molecules without concomitant increase in toxicity are also provided.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 9/62 - Organic coatings containing carbohydrates or derivatives thereof
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/67 - General methods for enhancing the expression
• A61K 9/64 - Organic coatings containing proteins or derivatives thereof
• C12N 15/64 - General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Abstract

Disclosed herein are functionalized polyethylenimine compounds for use as nanoparticles. Methods of making the compounds and nanoparticles comprising a cargo and methods of delivering a nanoparticle comprising a cargo are provided. The nanoparticles of the present invention can be utilized in methods of delivering cargo in a tissue specific manner, providing low toxicity and efficient release of cargo in the cell.

IPC Classes  ?

• C08G 73/02 - Polyamines
• A61K 9/51 - Nanocapsules
• G01N 33/545 - Synthetic resin
• A61K 31/785 - Polymers containing nitrogen
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

A post-fabrication method for drug loading a medical device with an active pharmaceutical ingredient (API). Such medical devices can include a polymer matrix, where the polymer matrix, after exposure to a loading solution with the API, can exhibit a degree of swelling of the polymer matrix and/or a degree of swelling in which the polymer matrix increases in a dimension along an axis. Medical devices including a polymer matrix and an API are provided, where the API is loaded into the polymer matrix by adsorption and/or swelling after fabrication of the polymer matrix, wherein the medical device provides a substantially sustained release of the API for an extended period of time. The medical devices include intravaginal rings (IVR). Methods of treating a subject using the disclosed medical devices are also provided, including treating a subject with an IVR with one or more APIs loaded therein.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61F 6/08 - Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
• A61K 31/52 - Purines, e.g. adenine
• A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61P 31/18 - Antivirals for RNA viruses for HIV

Abstract

Described herein are compounds for modifying meiotic recombination in a plant. In addition, described herein are methods of modifying meiotic recombination in a plant, including methods that can reduce linkage drag in a plant, increase recombination in a cold region of the genome of a plant, and/or reduce the number of backcross generations in a plant breeding method.

IPC Classes  ?

• A01H 1/00 - Processes for modifying genotypes
• A01H 3/04 - Processes for modifying phenotypes by treatment with chemicals
• A01N 29/04 - Halogen directly attached to a carbocyclic ring system
• A01N 33/02 - AminesQuaternary ammonium compounds

Abstract

Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables R1-10 are disclosed herein. The compounds are useful for treating central nervous system disorders, especially those involving substance use disorder and/or withdrawal syndrome. Pharmaceutical compositions containing compounds of Formula I or Formula II or Formula III and methods of treatment comprising administering compounds of Formula I or Formula II or Formula III are also disclosed.

IPC Classes  ?

• C07D 413/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
• A61K 31/424 - Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
• A61K 31/426 - 1,3-Thiazoles
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 207/416 - 2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
• C07D 277/14 - Oxygen atoms
• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 498/10 - Spiro-condensed systems

Abstract

The subject matter contained herein relates generally to methods and compounds that facilitate aliphatic carbon-hydrogen bond functionalization by group transfer via a nitrogen-centered radical in the presence of a trap, and the functionalized compounds prepared therefrom. The subject matter described herein provides a platform and the ability to efficiently and selectively introduce a range of valuable functionality on diverse hydrocarbon substrates ranging from methane to polyolefins with >3500 carbon atoms. As described herein, the reagents employed can form reactive N-centered radicals, the kinetics of which do not compete with companion radical traps. This technology finds usefulness in enhancing capabilities in late-stage diversification, while the molecules and materials now made accessible can provide solutions to important challenges in medicinal chemistry and materials science.

IPC Classes  ?

• C08F 8/32 - Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
• C07C 259/10 - Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings

Abstract

As described herein, the dark count rate (DCR) of perovskite photon-counting detectors (PCDs) was dominated by charge de-trapping from shallow traps located at the grain boundaries and surface, and the ultra-low DCR was achieved by suppressing the shallow traps by enhancing grain size and passivating film surface with diphenyl sulfide. The suppression of shallow traps made the perovskite PCDs have 100-1000 times lower DCR and much better response linearity to weak light than SiPMs, and the DCR was not sensitive to temperature due to small activation energy of charge traps. The zero-bias operating perovskite PCDs were demonstrated as γ-ray spectrum detectors with better energy resolution under 57Co source than commercial SiPMs at room temperature. At higher temperature up to 85 ℃, the perovskite PCDs are much superior to SiPMs by maintaining the energy resolution, showing their potential of working in harsh environment. This study discovered regular surface passivation also dramatically impact shallow charge traps, which should have implication of perovskite stability and doping.

IPC Classes  ?

• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
• H01L 31/075 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PIN type, e.g. amorphous silicon PIN solar cells
• H10K 30/88 - PassivationContainersEncapsulations
• H10K 71/12 - Deposition of organic active material using liquid deposition, e.g. spin coating
• H10K 30/81 - Electrodes
• H10K 30/85 - Layers having high electron mobility, e.g. electron-transporting layers or hole-blocking layers
• H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
• H10K 30/60 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation in which radiation controls flow of current through the devices, e.g. photoresistors

Abstract

The present invention provides methods and compositions comprising an adeno-associated virus (AAV) capsid protein, comprising one or more amino acids substitutions, wherein the substitutions introduce a new glycan binding site into the AAV capsid protein.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/075 - Adenoviridae
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors

Abstract

The present disclosure relates to rearranging an all-carbon backbone of a polymer to a nitrogen-containing backbone using an 2-aza-Cope rearrangement. Furthermore, these newly formed polymers with their nitrogen-containing backbones can be depolymerized into one or more non-polymeric nitrogen-containing molecules.

IPC Classes  ?

• C08G 12/06 - Amines
• C08F 8/28 - Condensation with aldehydes or ketones
• C08F 8/32 - Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
• C08F 36/04 - Homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, at least one having two or more carbon-to-carbon double bonds the radical having only two carbon-to-carbon double bonds conjugated
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation

Abstract

The present disclosure provides compositions and methods related to the treatment of ocular diseases in equines. In particular, the present disclosure provides novel compositions and methods related to the administration of therapeutic compositions comprising AAV-equine IL-10 for the treatment and/or prevention of various ocular diseases (e.g., non-infectious uveitis).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents
• C07K 14/54 - Interleukins [IL]
• C12N 15/86 - Viral vectors

Abstract

A flow cell is provided that includes surface-attached structures in a chamber. The structures are movable in response to an actuation force. The flow cell may be utilized to extract or isolate nucleic acids from a sample flowing through the flow cell, wherein some portion of the flow cell comprises nucleic acid adsorbant material (e.g. the outer surface of the surface-attached structures, an inside surface of the chamber of the flow cell, beads attached to the outer surface of the surface-attached structures, or beads integrated into the outer surface of the surface-attached structures). Further, systems and methods for extraction of nucleic acids using such flow cells are also provided.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

Provided herein are antibodies and antibody fragments that bind to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein RBD-targeting antibody.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Novel lysosomal acid lipase (LAL) positron emission tomography ligands are provided. Also disclosed herein are methods of assessing the risk of developing Alzheimer's disease (AD) or Alzheimer's Disease Related Dementias (ADRD) and methods of diagnosing AD/ADRD in a subject comprising measuring levels of LAL and optionally LAL accumulation in the subject. Methods of treatment comprising administering LAL are also provided.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61K 31/433 - Thiadiazoles
• C07D 285/13 - Oxygen atoms

Abstract

Methods of synthesizing chondroitin sulfate oligosaccharides are provided. Enzymatic schematic approaches to synthesizing structurally defined homogenous chondroitin sulfate oligosaccharides at high yields are provided. Synthetic chondroitin sulfate oligosaccharides ranging from 3-mers to 15-mers are provided.

IPC Classes  ?

• C07H 3/06 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• C07H 11/00 - Compounds containing saccharide radicals esterified by inorganic acidsMetal salts thereof
• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• C12N 9/10 - Transferases (2.)
• C12P 19/26 - Preparation of nitrogen-containing carbohydrates

Abstract

This invention relates to methods and compositions for binding antibodies. The methods may be used to isolate antibodies, treat disorders related to excess antibodies, acutely block antibodies to stop an autoimmune or inflammatory response, and inhibit neutralizing antibodies. In embodiments, the invention relates to methods of inhibiting neutralizing antibodies against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of Mycoplasma protein M or a functional fragment or derivative thereof, thereby inhibiting neutralization of the heterologous agent. The invention further relates to modified Mycoplasma protein M or functional fragments thereof having increased thermostability relative to wild-type protein M and their use in the methods of the invention.

IPC Classes  ?

• C07K 14/30 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 37/00 - Drugs for immunological or allergic disorders
• C12N 15/86 - Viral vectors

Abstract

The present invention provides a glucose dehydrogenase having an improved specific activity. A polypeptide comprising an amino acid sequence having such a structure that an amino acid residue at position-578 is substituted by a valine residue or a phenylalanine residue in the amino acid sequence represented by SEQ ID NO: 1, and a variant of the polypeptide have an improved glucose dehydrogenase activity.

IPC Classes  ?

• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase
• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose

Abstract

The invention relates to inverted chimera siRNA molecules and their use for the inhibition of expression of one or more target genes. The invention further relates to the inhibition of expression of c-Myc, or the dual inhibition of c-Myc and KRAS, using RNA interference, chemically-modified oligonucleotides, and/or chimeric siRNA multivalent combinations.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A method for colonoscopic blind spot detection includes receiving, as input, a video stream captured by a colonoscopic camera during a colonoscopy procedure and selecting, as output, video frames from the video stream containing information for generating a model of colonic surfaces. The method further includes identifying pixel depths and surface normals of the colonic surfaces. The method further includes refining the surface normals using scene illumination information. The method further includes refining the pixel depths using the refined surface normal. The method further includes estimating a camera pose for each of the video frames using the refined surface normals and refined depths. The method further includes generating the model of the colonic surfaces using the camera poses. The method further includes identifying blind spots in the model. The method further includes displaying indications of the blind spots.

IPC Classes  ?

• G06T 7/00 - Image analysis
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 3/02 - Neural networks
• G06N 20/00 - Machine learning
• G06T 17/00 - 3D modelling for computer graphics

Abstract

There are numerous enzymes reported which are categorized as nicotinamide adenine dinucleotide (NAD) or nicotinamide adenine dinucleotide phosphate (NAD(P), also referred to as NAD(P)) dependent dehydrogenases. Target molecules are oxidized by using NAD(P) as a cofactor, such that the enzyme oxidizes the target molecule while reducing the co-factor NAD(P) to NAD(P)H. In order to use NAD(P)-dependent dehydrogenases in biosensing applications, NAD(P) must be added to the reaction solution as it is not bound to the enzyme. Therefore, development technologies and methods to utilize NAD(P)H dependent dehydrogenases for electrochemical/optical analyses without using soluble redox mediator are strongly desired.

IPC Classes  ?

• C12N 9/02 - Oxidoreductases (1.), e.g. luciferase
• C12Q 1/32 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving oxidoreductase involving dehydrogenase
• C12Q 1/54 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving glucose or galactose
• C12N 15/80 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi

Abstract

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as neurological modulators (e.g., anti-nociceptive agents, antidepressants, anxiolytics, antipruritics). Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a core and three different arms as is shown in Formula (A) below.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/4196 - 1,2,4-Triazoles
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/33 - Heterocyclic compounds

Abstract

Disclosed herein is an easel assembly that can provide portability and versatility. The easel assembly can include a recessed docking interface that can allow for a stable and secure engagement with a docking arm or support arm while also enabling the easel assembly to maintain stability when undocked. The easel assembly can allow for easy setup and breakdown, making it easy to transport and use in a variety of indoor and outdoor settings. The docking interface can enable attachment to a wide range of vehicles, maintaining a stable interface when attached and providing the convenience of displaying and using various materials while on the go. The easel assembly can include manipulatable features on the support arm, allowing for adjustments to the angle or orientation of the top surface of the easel assembly, making it easy to set up or adjust the easel assembly to a desired angle and orientation. The disclosed easel assembly can provide a versatile and easy-to-use platform for displaying and using various materials in a range of settings and environments.

IPC Classes  ?

• A47B 97/04 - Easels or stands for blackboards or the like
• F16M 11/20 - Undercarriages with or without wheels

Abstract

The present disclosure relates to bifunctional chemical epigenetic modifiers, and methods of making, kits and using the bifunctional chemical epigenetic modifiers. The bifunctional chemical epigenetic modifiers can include a FK506 molecule or derivative thereof, a linker and a bifunctional ligand. The bifunctional ligand can be a histone deacetylase inhibitor.

IPC Classes  ?

• C12N 9/90 - Isomerases (5.)
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 38/15 - DepsipeptidesDerivatives thereof
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Injectable, biodegradable and removable polymer based drug suspension for ultra-long-acting drug delivery are disclosed. Ultra-long-acting in-situ forming implant (ISFI) drug suspension delivery systems as multipurpose prevention technologies for a multitude of applications are also provided. Methods of use, including treatment of subjects, using the disclosed compositions and ISFIs are also provided.

IPC Classes  ?

• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

This specification describes systems and methods for using Zero Echo Time (ZTE) magnetic resonance imaging (MRI) sequences for applications to functional MRI (fMRI). In some examples, a system for functional magnetic resonance imaging includes a magnetic resonance imaging (MRI) scanner and a control console implemented on at least one processor. The control console is configured for executing, using the MRI scanner, a zero echo time (ZTE) pulse sequence; acquiring, using the MRI scanner, magnetic resonance data in response to the ZTE pulse sequence; and constructing at least one MRI image using the magnetic resonance data and measuring tissue oxygenation (PtO2)-related T1 changes as a proxy of neural activity changes of a subject using the at least one MRI image.

IPC Classes  ?

• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G01R 33/48 - NMR imaging systems

Abstract

Described herein are perovskite films comprising a composition of Formula I (ABXs) and a compound of Formula II wherein A, B, X, D, R1and R2 are as defined herein. Further described are precursor perovskite solutions, methods for preparing the perovskite films, and use of the films in solar cells. As shown herein, solar cells fabricated using the perovskite films containing ammonium cations of Formula II as additives achieve enhanced efficiency and much improved thermal stability.

IPC Classes  ?

• C01G 21/16 - Halides
• C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
• H10K 30/15 - Sensitised wide-bandgap semiconductor devices, e.g. dye-sensitised TiO2
• H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
• H01L 31/075 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof adapted as photovoltaic [PV] conversion devices characterised by at least one potential-jump barrier or surface barrier the potential barriers being only of the PIN type, e.g. amorphous silicon PIN solar cells
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/81 - Electrodes

Abstract

Disclosed herein is the discovery of two telomere-encoded dipeptide repeat proteins, repeating VR protein and repeating GL protein. The properties of the proteins and their association with telomere health, biological age, and cancer are disclosed. Antibodies specific for telomere-encoded dipeptide repeat proteins, methods for detecting the proteins, and therapeutic approaches are also provided herein.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

This invention relates to methods and compositions for inhibiting or depleting antibodies, e.g., total IgG including neutralizing antibodies. In particular, the invention relates to methods of inhibiting or depleting antibodies against a heterologous agent when the heterologous agent is administered to a subject, comprising administering to the subject an effective amount of recombinant or modified Streptococcus pyogenes IgG degrading enzyme (IdeS) prepared from codon-optimized nucleic acids and/or modified nucleic acids, thereby inhibiting or depleting antibodies and inhibiting neutralization of the heterologous agent, e.g., to improve viral vector-mediated gene therapy.

IPC Classes  ?

• C12N 9/52 - Proteinases derived from bacteria
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy

Goods & Services

Downloadable publications in the field of education, early childhood development, mental health, and maternal and child health Online publications in the field of education, early childhood development, mental health, and maternal and child health; Consulting services in the field of education, early childhood development, mental health, and maternal and child health; Online blog in the field of education, early childhood development, mental health, and maternal and child health

Abstract

The present disclosure relates to selenium containing compounds useful as cellular labeling and barcoding reagents, such as isotopically-pure selenium maleimide compounds and the use thereof.

IPC Classes  ?

• C07D 421/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The subject matter described herein is directed to compounds of Formula A: and pharmaceutically acceptable salts thereof, and compositions thereof, including pharmaceutical compositions, and methods of treating disorders associated with TAM receptor tyrosine kinases and/or TYRO3.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
• A61P 35/00 - Antineoplastic agents
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 31/12 - Antivirals

Abstract

The present disclosure provides a model of human fibrolamellar hepatocellular carcinoma (FL-HCC) cells maintained as a transplantable tumor line in a host and a method to establish a transplantable human FL-HCC tumor line. Methods of ex vivo cultures of the FL-HCC are provided. Methods of diagnosing and treating FL-HCC tumors are also provided.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• A01K 67/0271 - Chimeric vertebrates, e.g. comprising exogenous cells
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The disclosure is directed to compounds that bind to a target RNA molecule, such as a TPP riboswitch, compositions comprising the compounds, and methods of making and using the same. The compounds contain two structurally different fragments that allow for binding with the target RNA at two different binding sites thereby producing a higher affinity binding ligand compared to compounds that only bind to a single RNA binding site.

IPC Classes  ?

• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• C07D 241/42 - Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring

Abstract

A method for spontaneous emulsification comprising mixing (i) an aqueous phase comprising a partitioning agent which contains a partitioning anion which determines the hydrophilicity of the partitioning agent, alone or in further combination with an electrolyte, with (ii) an oil phase comprising a phase-transfer agent, wherein the phase-transfer agent creates and promotes an interfacial flux of an anion and promotes the formation of droplets at a liquid-liquid interface of the aqueous phase and oil phase; and a method for spontaneous electro-emulsification comprising generating an ionic flux across the liquid-liquid interface by applying an electrical potential.

IPC Classes  ?

• B01F 23/411 - Emulsifying using electrical or magnetic fields, heat or vibrations
• B01F 23/41 - Emulsifying

Abstract

e.g., e.g., arthritis, or graft rejection in a subject, and compositions useful for the treatment of the autoimmune condition or graft rejection are also provided.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

This invention relates to methods and compositions for gene therapy. In particular, the invention relates to methods and compositions for modulating transgene expression from transgene delivery vectors by recruiting epigenetic modifiers to the vector. Using these methods, transgene delivery vectors can be more precisely regulated to produce increased amounts of the transgene product when needed and to decrease expression when needed, thereby providing maximum benefits for gene therapy while minimizing toxicity.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 38/12 - Cyclic peptides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

nparaparapara-cyanopyridylalanine

IPC Classes  ?

• C40B 30/04 - Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof
• C40B 40/10 - Libraries containing peptides or polypeptides, or derivatives thereof
• C40B 50/06 - Biochemical methods, e.g. using enzymes or whole viable microorganisms

Abstract

A transoral robotic surgery (TORS) simulator system includes a three-dimensional human head model having an oral cavity made of a synthetic material. The oral cavity has a mandible structure and a simulated human tongue and/or a simulated human tonsil. The simulated human tongue and/or the simulated human tonsil are made from a silicone material. The simulator system also includes artificial tissue(s) attached within the oral cavity, the artificial tissue being formed to mimic a biological tissue, whether cancerous (e.g., a tumor) or otherwise. The simulator system also includes a marker material present on and/or within the artificial tissue; the marker material allows a user of the simulator system to visually differentiate between the artificial tissue and synthetic material of the oral cavity.

IPC Classes  ?

• G09B 23/34 - Anatomical models with removable parts
• G09B 23/30 - Anatomical models

Abstract

Provided is a composition for targeting OTUD7B. The composition includes a component sufficient to block or reduce OTUD7B-mediated deubiquitination of GβL in a cell. The component can include 7Bi and variants thereof. Also provided are methods of treating cancer and related conditions, including administering to a cancer patient a OTUD7B catalytic inhibitor, including a 7Bi or variant thereof.

IPC Classes  ?

• C07D 231/10 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
• C07D 231/02 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings

Abstract

Provided herein are small molecule compounds, including non-anticoagulant heparan sulfate oligosaccharide molecules, having anti-inflammatory properties and capable of interacting with high mobility group box 1 (HMGB1) proteins in a manner sufficient to affect an interaction between the HMGB1 protein and a receptor for advanced glycation end products (RAGE). Also provided herein are methods of treating Paracetamol (APAP) overdose in subjects.

IPC Classes  ?

• A61K 31/727 - HeparinHeparan

Goods & Services

Educational services, namely providing courses of instruction at the undergraduate level in the field of international business

Abstract

The present disclosure provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The disclosure also provides methods of administering the virus vectors and virus capsids of the disclosure to a cell or to a subject in vivo.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors

Abstract

Disclosed are compositions for targeting 0TUD7A, the compositions having a component sufficient to block and/or reduce OTUD7A-mediated deubiquitination of EWS-FLI1 in a cell. The component can be 7Ai and variants thereof. The compositions can be used to treat Ewing sarcoma (EWS). Methods of using the disclosed compositions are also disclosed, including methods of treating EWS in a subject.t

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 35/00 - Antineoplastic agents

Abstract

A method of calculating a set of desired transport routes for a stroke patient comprises selecting a set of destination points, comprising a first stroke center and a second stroke center, generating a set of infarct core growth models for stroke patients along at least a first path from a starting point to the first stroke center followed by an optional trip to the second stroke center, and a second path from the starting point to the second stroke center, varying a set of parameters of the stroke patients, calculating a model of patient outcomes from each origin point, and designating whether the first path or the second path is preferable based on the probabilistic model. A system for displaying a desired transport route for a stroke patient and a method of calculating a preferred location for a mobile treatment unit in a geographic region are also described.

IPC Classes  ?

• G06Q 10/047 - Optimisation of routes or paths, e.g. travelling salesman problem
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Interferon-γ-inducible protein 10 (IP-10) peptides, IP-10 peptide variants and in silico designed C-X-C chemokine receptor 3 (CXCR3) peptide agonists are described. The small peptides can be used for inhibiting pathological tissue remodeling and treating fibrosis in a subject, such as a subject with fibrosis of the heart, lung, liver, kidney or skin. The peptide agonists can also be used to treat cardiovascular disease, including myocardial infarction and ischemia-reperfusion injury. Also described are in silico designed peptide antagonists that bind CXCR3 or ligands of CXCR3. These antagonist peptides block CXCR3 signaling by disrupting interaction of CXCR3 with its ligand. Antagonist peptides can be used, for example, to treat myocarditis and atherosclerosis. In additional embodiments agonists and antagonists of CXCR4 are disclosed.

IPC Classes  ?

• A61K 38/19 - CytokinesLymphokinesInterferons
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 35/00 - Antineoplastic agents
• C07K 7/02 - Linear peptides containing at least one abnormal peptide link
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/86 - Viral vectors

Abstract

Described herein are surface treatment methods for removing one or more surface defect layers from polycrystalline films, polycrystalline films that are free of one or more defect surface layers, and use of the films in solar cells. In certain embodiments, the method is conducted by means of an adhesive tape or mechanical polishing. As described herein, solar cells containing the surface treated perovskite films show enhanced efficiency and stability.

IPC Classes  ?

• H10K 71/20 - Changing the shape of the active layer in the devices, e.g. patterning
• B08B 7/00 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass
• C07F 7/24 - Lead compounds
• C07F 19/00 - Metal compounds according to more than one of main groups
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Abstract

The present inventive concept provides a therapeutic platform that will prevent disease and reverse disease morbidity and mortality wherein the causative agent is a member of a broad class of infectious disease agents that mediate pathogenesis via mechanisms that are ameliorated by an interferon. The platform is based on the construction of single-chain soluble fusion proteins including a pathogen recognition domain, a linker and a pathogenesis-inhibiting effector domain.

IPC Classes  ?

• C07K 14/565 - IFN-beta
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)

Abstract

Devices and methods for generating an aerosol of a therapeutic agent and methods of using and preparing the same are disclosed. The device includes a heatable porous substrate (e.g., a porous metal or metal alloy) embedded with a composition containing a vaporizable carrier compound (e.g., a phospholipid) and at least one therapeutic agent. The device can be incorporated into a delivery device, such as a metered dose inhaler or an exposure chamber. When the heatable porous substrate is heated, such as by resistive heating, the carrier compound is vaporized and both it and the at least one therapeutic agent are carried out of the porous substrate and, upon cooling, form aerosol particles comprising the at least one therapeutic agent.

IPC Classes  ?

• A61M 11/04 - Sprayers or atomisers specially adapted for therapeutic purposes operated by the vapour pressure of the liquid to be sprayed or atomised

Abstract

The present disclosure provides humanized antibodies and antigen-binding fragments thereof that specifically bind to SFRP2 and compositions comprising such humanized antibodies or antigen-binding fragments thereof. In some aspects, the humanized antibodies or antigen-binding fragments can be used to treat diseases or conditions associated with increased SFRP2, such as cancer. In some aspects, the antibodies or antigen-binding fragments can be used to treat osteosarcoma.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Abstract

The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.

IPC Classes  ?

• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/428 - Thiazoles condensed with carbocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

This invention relates synthetic modified polypeptides which bind to the Orai1 calcium channel, and their therapeutic use as lung immunomodulators in disorders such as, but not limited to, viral infections, bacterial infections, allergic responses, asthma, cystic fibrosis and other inflammatory disorders.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 11/06 - Antiasthmatics
• A61P 31/04 - Antibacterial agents
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/02 - Immunomodulators
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression